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Fibroblast proliferation and generation of pro-
visional extracellular matrix (ECM) are primary 
tissue responses to injury (Tomasek et al., 2002). 
Successful  wound  repair  processes  are  tightly 
regulated, with a balance of ECM synthesis and 
resolution as well as reepithelization (Tomasek 
et al., 2002). Uncontrolled ECM production 
can lead to clinically important fibrotic diseases, 
including  idiopathic  pulmonary  fibrosis  (IPF) 
(Tomasek et al., 2002; Thannickal et al., 2004). 
An important pathological feature of IPF is the 
presence of fibroblastic foci in the lungs, and 
the presence and extent of such fibroblastic   
foci is one of the most reliable markers of poor 
prognosis in patients with IPF (Wynn, 2007; 
Hardie et al., 2009). Fibroblastic foci are aggre-
gations of fibroblasts/myofibroblasts that pro-
duce  excessive  ECM  components  (Wynn, 
2007; Hardie et al., 2009). TGF-1 has been 
shown to be an important mediator of lung fi-
brosis and can induce differentiation of pulmo-
nary fibroblasts into myofibroblasts characterized 
by -smooth muscle actin (-SMA) expression 
and active synthesis of ECM proteins (Lee et al., 
2006; Cutroneo et al., 2007).
microRNAs (miRNAs) are a class of non-
coding small RNAs, 22 nt in length, which 
bind to the 3 UTR of target genes and thereby 
repress translation of target genes and/or in-
duce degradation of target gene mRNA (Stefani 
and Slack, 2008). miRNAs play essential roles 
in numerous cellular and developmental pro-
cesses, including intracellular signaling path-
ways  and  organ  morphogenesis  (Stefani  and 
Slack, 2008). Aberrant expression of miRNAs 
is closely associated with initiation and progres-
sion  of  pathophysiologic  processes  including 
diabetes,  cancer,  and  cardiovascular  disease 
(Thum et al., 2008; Croce, 2009; Latronico 
and  Condorelli,  2009;  Pandey  et  al.,  2009). 
However, the role of miRNAs in lung fibrosis 
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Uncontrolled extracellular matrix production by fibroblasts in response to tissue injury 
contributes to fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), a progressive 
and ultimately fatal process that currently has no cure. Although dysregulation of miRNAs 
is known to be involved in a variety of pathophysiologic processes, the role of miRNAs in 
fibrotic lung diseases is unclear. In this study, we found up-regulation of miR-21 in the 
lungs of mice with bleomycin-induced fibrosis and also in the lungs of patients with IPF. 
Increased miR-21 expression was primarily localized to myofibroblasts. Administration of 
miR-21 antisense probes diminished the severity of experimental lung fibrosis in mice, even 
when treatment was started 5–7 d after initiation of pulmonary injury. TGF-1, a central 
pathological mediator of fibrotic diseases, enhanced miR-21 expression in primary pulmo-
nary fibroblasts. Increasing miR-21 levels promoted, whereas knocking down miR-21  
attenuated, the pro-fibrogenic activity of TGF-1 in fibroblasts. A potential mechanism  
for the role of miR-21 in fibrosis is through regulating the expression of an inhibitory 
Smad, Smad7. These experiments demonstrate an important role for miR-21 in fibrotic 
lung diseases and also suggest a novel approach using miRNA therapeutics in treating 
clinically refractory fibrotic diseases, such as IPF.
© 2010 Liu et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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d 7 (Fig. 1 D). TGF-1 returned to basal levels on d 24 after 
bleomycin administration, consistent with previous studies 
(Zhang et al., 1995). To further delineate the role of TGF-1 
in the enhanced expression of miR-21 in fibrotic lungs, we 
used transgenic mice that inducibly express a dominant-
negative form of TGF-1RII (Ambalavanan et al., 2008), 
which  can  inhibit  TGF-1  downstream  signaling  events   
by  blocking  TGF-1–induced  formation  of  endogenous 
TGF-1RI-II complex. As shown in Fig. S1 C, the en-
hanced expression of miR-21 was significantly attenuated 
in  the  mice  expressing  dominant-negative  TGF-1RII   
after bleomycin administration. These results suggest that 
TGF-1 plays an important role in mediating the increased 
expression of miR-21, although other mechanisms may 
also be involved.
In situ hybridization (ISH) of mouse lungs showed only 
minimal cytoplasmic staining for miR-21, but dramatic in-
creases after bleomycin treatment (Fig. 1 E, i-ii). The expres-
sion of miR-21 appeared in sheets in the lung parenchyma, 
consistent with the pattern of fibroblast/myofibroblast accu-
mulation in bleomycin-treated lungs (Fig. 1 E, ii). In contrast, 
there  was  only  minimal  background  staining  using  control 
probes with scrambled sequence, supporting the specificity of 
the miR-21 staining (Fig. 1 E, iii). To determine if miR-21 was 
indeed expressed in pulmonary myofibroblasts in bleomycin-
treated  lungs,  immunohistochemistry  was  performed  along 
with ISH and demonstrated that miR-21 expression was pri-
marily colocalized with that for -SMA (Fig. 1 F), suggesting 
that  myofibroblasts  were  the  main  source  of  the  increased 
miR-21 levels present in bleomycin-treated lungs. Lungs from 
patients with IPF also showed increased expression of miR-21 
(Fig. 1 G), with expression primarily localized to the fibroblas-
tic foci (Fig. 1 H, i). Taken together, these data suggest that 
miR-21 may participate in the pathogenesis of lung fibrosis by 
regulating fibroblast/myofibroblast activation.
To determine if miR-21 is involved in the development 
of experimental lung fibrosis, we used locked nucleic acid 
(LNA)–modified  miR-21  antisense  probes  to  modulate 
miR-21 expression. LNA-modified miRNA antisense probes 
were previously shown to be capable of effectively seques-
tering  miR-122  in  vivo  by  forming  duplexes  with  this 
miRNA (Elmén et al., 2008). Intratracheal instillation of 
miR-21 antisense probes before bleomycin administration 
completely  sequestered  miR-21,  as  demonstrated  by  the 
formation  of  miR-21:anti-miR-21  duplexes  (bands  with 
retarded migration) in lungs harvested 2 wk after bleomycin 
administration (Fig. 2 A). Real-time PCR demonstrated   
no mature miR-21 expression in miR-21 antisense probe-
treated  lungs,  whereas  the  expression  of  an  unrelated 
miRNA, miR-155, was not affected by administration of 
the miR-21 antisense probes, consistent with specific tar-
geting of miR-21 by the antisense probes (Fig. 2 B). Treat-
ment with miR-21 antisense probes prevented the enhanced 
collagen  deposition  (Fig.  2  C)  and  elevated  expression   
of ECM proteins, such as Fn and collagen, at both RNA 
and protein levels that occur in the lungs after bleomycin 
is just beginning to unravel (Pandit et al., 2010). Therefore, 
determining the roles of specific miRNAs involved in the 
pathogenesis of lung fibrosis is likely to suggest important 
new directions for the treatment of IPF and other interstitial 
lung diseases.
In the present study, we explored the role of miRNA in 
the pathogenesis and progression of lung fibrosis. We found 
that miR-21 is highly up-regulated in the lungs of mice with 
bleomycin-induced lung fibrosis and in the lungs of patients 
with IPF. The enhanced expression of miR-21 is primarily 
located to myofibroblasts in the fibrotic lungs. In addition, 
miR-21 is up-regulated by TGF-1 and functions in an am-
plifying circuit to enhance the fibrogenic activity of TGF-1 
in human primary fibroblasts. More importantly, we found that 
miR-21 sequestration in mouse lungs attenuates bleomycin- 
induced lung fibrosis. Overall, these data suggest that miR-21 is 
a central mediator in the pathogenesis of lung fibrosis and a 
potential target for developing novel therapeutics in treating 
fibrotic diseases, including IPF.
RESULTS AND DISCUSSION
To investigate if miRNAs may participate in the pathogen-
esis and progression of lung fibrosis, we identified miRNAs 
whose expression was altered in fibrotic lungs. A miRNA 
array assay was performed on RNA isolated from the lungs 
of mice that had been given intratracheal PBS or bleomycin 
for 1 or 2 wk, a well-characterized model of lung fibrosis 
(Moore and Hogaboam, 2008). We found that a number of 
miRNAs had significantly altered expression in bleomycin-
exposed lungs (Fig. S1, A and B). Of these miRNAs, miR-21 
demonstrated the greatest increase in expression. miR-21 
has  previously  been  shown  to  be  induced  in  TGF-1–
treated human vascular smooth muscle cells and to regulate 
the  expression  of  genes  involved  in  the  contraction  of 
smooth muscle (Davis et al., 2008). Because TGF-1 is a 
central pathological mediator of lung fibrosis (Cutroneo   
et al., 2007; Moore and Hogaboam, 2008), the induction of 
miR-21 by TGF-1 suggests that miR-21 may have a po-
tential role in the pathogenesis of lung fibrosis. To validate 
the miRNA array data, Northern blotting was performed 
and showed that miR-21 was up-regulated in lungs from 
bleomycin-exposed mice as early as d 3 after bleomycin ad-
ministration,  reached  its  highest  levels  on  d  14,  and  re-
mained at the highest level until at least 24 d after bleomycin 
administration (Fig. 1 A). Real-time PCR analysis on the 
same set of samples demonstrated similar results to North-
ern blotting (Fig. 1 B). Of note, expression of the extracel-
lular matrix protein, fibronectin, was also up-regulated with 
similar timing as to miR-21 (Fig. 1 C). These data suggest 
that the enhanced expression of miR-21 is involved in the 
progression of lung fibrosis.
To demonstrate if TGF-1 contributed to the enhanced 
expression of miR-21 in the fibrotic lungs, we examined 
pulmonary  levels  of  TGF-1  and  found  that,  similar   
to miR-21, TGF-1 expression started to rise at d 3 after 
bleomycin administration and reached maximal levels on   JEM VOL. 207, August 2, 2010  1591
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with  miR-21  antisense  probes;  this 
finding was confirmed by Masson’s 
trichrome staining, which highlights 
collagen deposition (Fig. 2 F). Likewise, 
pretreatment with miR-21 antisense 
probes prevented the accumulation of 
myofibroblasts in bleomycin-treated 
lungs, as demonstrated by immuno-
histochemistry staining with anti -SMA 
antibody (Fig. 2 G).
To  explore  if  inhibition  of  miR-21  has  therapeutic   
potential in the treatment of lung fibrosis, we administered 
miR-21 antisense probes i.p. once a day from d 5 to 7 after 
intratracheal instillation of bleomycin, a time when inflam-
matory responses start to subside and active fibrogenesis   
occurs (Vittal et al., 2005; Moore and Hogaboam, 2008), and 
then analyzed the extent of lung fibrosis 14 d after adminis-
tration of bleomycin. Under these conditions, the majority 
administration (Fig. 2, D and E). The control probes had no 
effects  on  bleomycin-induced  lung  fibrosis  (Fig.  S2  E). 
These data indicate that sequestration of miR-21 with anti-
sense probes prevents experimental pulmonary fibrosis. Of 
note, -SMA expression was not increased in bleomycin-treated 
lungs from mice given miR-21 antisense probes, suggesting 
a role for miR-21 in the induction of myofibroblast differentia-
tion (Fig. 2 E). H&E staining demonstrated dramatic attenua-
tion of bleomycin-induced lung fibrosis in mice pretreated 
Figure 1.  miR-21 is up-regulated in 
lungs from bleomycin-treated mice and 
from patients with IPF. (A) Total RNA was 
isolated from lungs harvested at the indicated 
time points after intratracheal bleomycin 
instillation (1.5 U/kg in 50 µl PBS). Northern 
blotting was performed to determine the 
levels of miR-21 and the loading control, 
small nucleolar RNA U6. (B-D) Real-time PCR 
was performed to determine the levels of 
miR-21 (B), fibronectin (C), and TGF-1 (D) in 
the same samples as in A. n = 3 mice in each 
group, mean ± SEM. **, P < 0.01; ***, P < 0.001 
compared with d 0. (E) Frozen sections were 
prepared from mouse lungs harvested at d 0 
and 14 after bleomycin instillation. In situ 
hybridization was performed to determine the 
localization of miR-21. Bars: 12.5 µm. (F) Fro-
zen sections were prepared from mouse lungs 
harvested at d 14 after bleomycin instillation. 
ISH and immunohistochemistry assays were 
performed to determine the colocalization of 
miR-21 and -SMA (i–iv). An additional slide 
was processed with H&E staining and an  
image was obtained from approximately the 
same regions as shown in i–iv (v). Bars:  
20 µm. Results in A–F represent one out of 
two to three independently performed experi-
ments with similar outcomes. (G) miR-21 
levels in histologically normal lungs collected 
during resection of lung cancer and in lungs 
from patients with idiopathic pulmonary fi-
brosis. Experiments were performed with RNA 
from 8 normal lungs and 8 IPF lungs. Mean ± 
SEM. *, P < 0.05 compared with control nor-
mal lungs. (H) In situ hybridization was per-
formed to determine the localization of 
miR-21 (i) in lung tissue of IPF patients. ISH 
with scrambled probes (ii). Bars: 20 µm. Ex-
periments were performed twice.1592 miR-21 regulates lung fibrosis | Liu et al.
Figure 2.  Sequestering miR-21 prevents bleomycin-induced lung fibrosis in mice. (A) Mice (n = 3–6 in each group) received either control probes 
or miR-21 antisense probes (10 mg/kg body weight in 50 µl PBS) intratracheally on d 4 and 2 before intratracheal instillation of bleomycin (1.5 U/kg in  
50 µl PBS) or PBS. At 14 d after bleomycin administration, mice were sacrificed and total RNA from lungs was isolated. Northern blotting was performed to 
determine miR-21 levels. U6 was the loading control. Representative results are shown. (B) Real-time PCR was performed to determine the levels of  
miR-21 and miR-155 in two samples from each group described in A. Mean ± SD. (C) Experiments were performed as described in A and collagen content in 
the right lungs was determined. n = 3–6 mice in each group. Mean ± SEM. **, P < 0.01 compared with PBS-treated mice given control probes. *, P < 0.05 
compared with bleomycin-treated mice given control probes. (D) Real-time PCR was performed to determine mRNA levels of Fn, Col1A1, and Col1A2 in 
the same samples analyzed in A. n = 3–6 mice in each group. Mean ± SD. ***, P < 0.001 compared with bleomycin-treated mice given control probes.  
(E) Experiments were performed as described in A. Protein levels of Fn, Col1A, -SMA, and GAPDH in lung homogenates were determined by Western 
blotting. Results in A–E represent one out of two independently performed experiments. (F) Experiments were performed as described in A. Pulmonary 
fibrosis, as assessed on d 0 and 14 after bleomycin administration, was determined in mice given control or miR-21 antisense probes. H&E staining and 
Masson’s trichrome blue staining for collagen. Bars: 100 µm. (G) Experiments were performed as described in A. -SMA expression was determined by 
immunohistochemistry on d 0 and 14 after bleomycin administration in the lungs of mice given either control probes or miR-21 antisense probes. Mouse 
IgG was used as a negative control for anti–-SMA antibodies. Bars: 50 µm. Data presented in F and G are representative of results from two indepen-
dent experiments with two to three mice in each group.JEM VOL. 207, August 2, 2010  1593
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and -SMA in pul-
monary  fibroblasts 
(Fig.  4  C).  Con-
versely,  knocking 
down  miR-21  at-
tenuated TGF-1–dependent transcription of Fn and -SMA 
(Fig. 4 D). Similarly, increasing miR-21 levels enhanced, 
whereas knocking down miR-21 attenuated, Fn and -SMA 
protein  levels  in  pulmonary  fibroblasts  (Fig.  4,  E  and  F).   
These data suggest that the anti-fibrotic effects of miR-21 
antisense probes may be mediated through regulation of 
TGF-1–related signaling events. Consistent with this hypoth-
esis, increasing miR-21 levels enhanced, whereas knocking 
down miR-21 attenuated, Smad2 phosphorylation in response 
to TGF-1 stimulation (Fig. 4, G and H).
Because miR-21 regulates TGF-1 signaling events under 
in vitro conditions in pulmonary fibroblasts, we expected 
that it also might have such actions in vivo. In bleomycin-
treated mice, administration of miR-21 antisense probes at-
tenuated Smad2 phosphorylation in the lungs (Fig. 4 I), an 
event mediated by TGF-1 activation (Wang et al., 2006). 
The computational algorithm TargetScan predicted that Smad7, 
an inhibitory Smad, is a miR-21 target. Consistent with this 
prediction, up-regulating miR-21 levels decreased, whereas 
blocking miR-21 increased, Smad7 expression in pulmonary 
fibroblasts (Fig. 4, J and K). Smad7 expression was also de-
creased in bleomycin-treated lungs, concomitant with en-
hanced miR-21 expression under these conditions. Treatment 
with  miR-21  antisense  probes  prevented  the  decrease  in 
Smad7  expression  in  bleomycin-treated  lungs  (Fig.  4  L). 
These data suggest that miR-21 targets Smad7 to enhance 
signaling events downstream of TGF-1. To determine if 
miR-21 directly regulates Smad7 expression, the 3 UTR of 
the Smad7 gene was cloned into a luciferase reporter, pMIR-
reporter. A 3 UTR mutant that contains mutations in the 
of mature miR-21 appeared to be sequestered (Fig. 3 A), 
and miR-21 antisense probes attenuated collagen deposi-
tion (Fig. 3 B) as well as Fn and collagen expression at both 
RNA and protein levels in bleomycin-treated lungs (Fig. 3,   
C and D). To further define the therapeutic potential of 
miR-21 sequestration, we administered miR-21 antisense 
probes intratracheally on d 7 after intratracheal instillation 
of bleomycin and then determined the extent of fibrosis   
in the lungs 3 wk after bleomycin injection. As shown in   
Fig. S2 A, intratracheal instillation of miR-21 antisense probes 
after bleomycin administration sequestered miR-21 in mouse 
lungs. Collagen deposition in the lungs was significantly   
attenuated  3  wk  after  bleomycin  administration  in  anti-
miR-21–treated mice (Fig. S2 B). Administration of miR-21 
antisense probes intratracheally on d 14 after intratracheal 
instillation of bleomycin was still able to attenuate lung fi-
brosis, although the effects were less significant than those 
in mice that were treated with anti–miR-21 probes at ear-
lier time points (Fig. S2, C and D).
Pulmonary fibroblasts are primary effectors of lung fi-
brotic diseases (Hinz et al., 2007). TGF-1 induces fibroblast 
differentiation  into  more  fibrogenic  myofibroblasts  (Hinz   
et al., 2007). We showed above that enhanced miR-21 ex-
pression in bleomycin-treated mice was primarily localized   
to -SMA–expressing myofibroblasts. To determine if the 
mechanisms leading to the anti-fibrotic effects of miR-21 an-
tisense probes in vivo involve potential regulation of fibro-
genic activities of pulmonary fibroblasts by miR-21, we 
studied the role of miR-21 in the activation of pulmonary fi-
broblasts by TGF-1. TGF-1 up-regulated miR-21 expres-
sion in a dose- and time-dependent manner in pulmonary 
fibroblasts (Fig. 4, A and B; Fig. S3 A), suggesting the poten-
tial  involvement  of  miR-21  in  TGF-1–related  signaling 
events. Increasing miR-21 levels by transfection of miR-21 
precursors enhanced TGF-1–induced transcription of Fn 
Figure 3.  Sequestering miR-21 dimin-
ishes the severity of bleomycin-induced 
lung fibrosis in mice. (A) Mice were given 
bleomycin intratracheally (1 U/kg in 50 µl 
PBS). On d 5, 6, and 7 after bleomycin admin-
istration, control probes or miR-21 antisense 
probes (10 mg/kg body weight in 200 µl PBS) 
were injected i.p. On d 14 after bleomycin 
instillation, mouse lungs were collected. 
Northern blotting was performed to deter-
mine miR-21 levels using U6 as a loading 
control. (B) Experiments were performed as 
described in A. Collagen content was mea-
sured in the right lungs. n = 3–5 in each 
group, values are shown as mean ± SEM.  
***, P < 0.001 compared with mice treated with 
PBS and control probes. **, P < 0.01 compared 
with mice treated with bleomycin and control 
probes. (C) Experiments were performed as 
described in A and mRNA levels of Col1A1, 
Col1A2, and Fn determined in lungs isolated 
from the treated mice. (D) Experiments were 
performed as described in A. Protein levels of 
Fn, Col1A, and GAPDH in lung homogenates 
were determined by Western blotting.  
Experiments were performed twice with  
similar results.1594 miR-21 regulates lung fibrosis | Liu et al.
Figure 4.  miR-21 is induced by TGF-1 and regulates the pro-fibrogenic activities of TGF-1. (A and B) MRC-5 human primary fibroblasts 
were treated with TGF-1 at the indicated concentrations for 48 h (A) or 10 ng/ml TGF-1 for the indicated length of time (B). miR-21 levels were deter-
mined by Northern blotting. The small nucleolar RNA, U6, was used as a loading control. The experiments were performed twice with similar results.  
(C and D) Fibroblasts were transfected with 30 nM control miRNA precursors (C), miR-21 precursors (C), control knockdown probes (D), or miR-21 knock-
down probes (D). 2 d after transfection, the fibroblasts were treated with 10 ng/ml TGF-1 for 48 h. miRNA levels of Fn and -SMA were determined. 
Each condition included 3–4 wells. Mean ± SD. **, P < 0.01; ***, P < 0.001 compared with TGF-1–treated cells transfected with control probes. Results 
represent one out of two to three independently performed experiments with similar outcomes. (E–H) Fibroblasts were transfected with control miRNA 
precursors (E and G), miR-21 precursors (E and G), control knockdown probes (F and H), or miR-21 knockdown probes (F and H), and after 48 h the cells 
were treated with 2 ng/ml TGF-1 for an additional 0, 24, or 48 h. Protein levels of Fn, -SMA, p-Smad2, and GAPDH were determined. Results in E–H 
represent one out of two to three independently performed experiments with similar outcomes. (I) Protein levels of p-Smad2 and Smad2 in the same 
samples as shown in Fig. 2 E. Densitometry was performed and fold increase in p-Smad2 expression after normalization to total Smad2 expression is 
shown. The value for the PBS group with control probes was considered to be 1. **, P < 0.01 compared with the PBS group; ***, P < 0.001 compared with 
the bleomycin group treated with control probes. Experiments were performed twice with similar results. (J–K) Fibroblasts were transfected with control 
miRNA precursors (J), miR-21 precursors (J), control knockdown probes (K), or anti-miR-21 probes (K), and 96 h later the cells were collected and protein 
levels of Smad7 and GAPDH were determined. The two individual bands separated by the line in J or K were from the same blot. Experiments were per-
formed at least three times. Densitometry analysis was performed and fold increase in Smad7 expression after normalization to GAPDH expression is shown. JEM VOL. 207, August 2, 2010  1595
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events, rather than abolishing the expression of a single pro-
tein (Bushati and Cohen, 2007; Lodish et al., 2008).
Although TGF-1 is an important mediator of fibrotic   
diseases, it may not be the only factor causing miR-21 up- 
regulation during fibrosis, as indicated by our data that miR-21 
was still up-regulated in the lungs of mice expressing dominant-
negative TGF-1RII after intratracheal administration of 
bleomycin, although to a lesser extent than in wild-type mice 
(Fig. S1 C). Other pro-fibrotic growth factors, such as EGF 
signaling, have been shown to regulate miR-21 expression in 
cancer cells (Seike et al., 2009). We found that bFGF, another 
important profibrotic growth factor involved in the pathogen-
esis of IPF (Inoue et al., 2002), enhances miR-21 expression in 
human primary fibroblasts (Fig. S3 B). Thus, dysregulation of 
miR-21 could arise from aberrations in multiple critical signal-
ing events involved in pulmonary fibrosis.
Our studies provide proof of concept and suggest a novel 
approach using miRNA therapeutics, specifically directed to 
miR-21, in treating clinically important fibrotic diseases such 
as IPF, for which cures have long been elusive.
MATERIALS AND METHODS
Experimental pulmonary fibrosis model. C57BL/6 mice were purchased 
from NCI-Frederick. Transgenic mice that inducibly express a dominant-
negative  form  of  TGF-1RII  were  a  gift  from  Drs.  Rosa  Serra  and   
Namasivayam Ambalavanan (University of Alabama at Birmingham, Birming-
ham, AL). To induce the expression of dominant-negative TGF-1RII, mice 
were given water containing 10 mM ZnSO4 for 2 wk before intratracheal 
administration of bleomycin and kept on ZnSO4-containing water for the en-
tire period of the experiments. As controls, wild-type mice were provided with 
the same ZnSO4-containing water. For bleomycin instillation, 8-wk-old mice 
were anesthetized with isoflurane. After the tongues of the anesthetized mice 
were gently pulled forward with forceps, bleomycin (from EMD; 1–1.5 U/kg 
body weight in 50 µl PBS) was delivered into the oropharyngeal cavity. The 
tongue was kept extended until all of the liquid was inhaled into the lungs. The 
mice were sacrificed at the indicated time points. The animal protocol was ap-
proved by the UAB Institutional Animal Care and Use Committee (IACUC).
Reagents. Human recombinant TGF-1 was purchased from PeproTech. 
LNA-modified control knockdown and miR-21 knockdown probes for   
in vivo applications were synthesized by Exiqon.
Cell culture. Human primary pulmonary cell lines, MRC-5 and IMR-90, 
as well as HEK-293 cells, were purchased from American Type Culture 
Collection (Manassas, VA). Cells were cultured at 37°C with 5% CO2 in 
DME containing 10% FBS.
Human lung tissue. 8 IPF lung tissue samples were obtained from surgical 
remnants of biopsies or lungs explanted from patients with IPF that under-
went pulmonary transplant and 8 controls were obtained through the Uni-
versity of Pittsburgh Health Sciences Tissue Bank from samples resected 
from patients with lung cancer. The protocol was approved by the Institu-
tional Review Board (IRB) of the University of Pittsburgh.
predicted miR-21 seeding sequence was also cloned into the 
pMIR-reporter (Fig. S4 A). Transfection of miR-21 precur-
sors significantly down-regulated luciferase activity for the 
reporter  containing  wild-type,  but  not  mutant,  Smad7  3 
UTR (Fig. 4 M), consistent with direct regulation of Smad7 
by miR-21. Furthermore, the Smad7-expressing vector con-
taining wild-type, but not mutant Smad7 3 UTR, was sub-
ject to regulation by miR-21 (Fig. 4 N).
In this study, we showed that expression of miR-21 is 
increased in the lungs of bleomycin-treated mice and in   
the lungs of patients with IPF. miR-21 expression was en-
hanced in locations with fibroblast/myofibroblast accumu-
lation and was localized to myofibroblasts. TGF-1–induced 
miR-21 expression and miR-21 in turn promoted TGF-1– 
induced  fibrogenic  activation  of  pulmonary  fibroblasts   
by targeting the inhibitory Smad, Smad7. Thus, miR-21 
appears to function in an amplifying circuit to enhance 
TGF-1  signaling  events  and  to  promote  fibrotic  lung   
diseases in which TGF- plays a contributory role, includ-
ing IPF.
miRNAs normally have multiple targets (Bushati and 
Cohen, 2007; Lodish et al., 2008). Though Smad7 was pre-
viously shown to negatively regulate lung fibrosis (Nakao   
et al., 1999; Shukla et al., 2009), inhibition of Smad7 may 
not be the sole mechanism by which miR-21 exerts pro- 
fibrogenic effects. For example, Spry1, a negative regulator 
of Erk activation, was previously shown to be a miR-21 
target (Thum et al., 2008). Erk activation has been dem-
onstrated to promote the fibrogenic activities of TGF-1 
(Ding et al., 2008). In our experiments, Spry1 was decreased 
in bleomycin-treated lungs, whereas Erk phosphorylation 
was increased (Fig. S4 B). The decrease in Spry1 expression 
and increase in Erk phosphorylation was prevented in the 
lungs of mice treated with miR-21 antisense probes (Fig. S4 B). 
In experimental models of myocardial infarction, phospha-
tase and tensin homologue (PTEN) was down-regulated by 
miR-21 in cardiofibroblasts from the infracted areas (Roy 
et al., 2009). Furthermore, PTEN has been shown to nega-
tively  regulate  experimental  lung  fibrosis  (White  et  al., 
2006). Such studies suggest that PTEN could also be in-
volved in the profibrotic effects of miR-21. Thus, miR-21 
occupies an important role in integrating functionally con-
nected  pathways  involved  in  pulmonary  fibrotic  disease 
through its ability to regulate multiple important signaling 
events involved in fibrogenesis. Targeting miR-21 in IPF 
may represent a better therapeutic strategy than approaches 
aimed at a single pathway. Our data highlight the ability of 
miRNAs to fine tune various cellular and developmental 
***, P < 0.001 compared with the group treated with control precursors; *, P < 0.05 compared with the group with control anti-miR probes. (L) Protein 
levels of Smad7 and GAPDH in the same samples shown in Fig. 2 E. Experiments were performed twice with similar results. (M) Luciferase reporters  
containing wild-type or mutant 3 UTR of mouse smad7 gene were cotransfected with control miRNA or miR-21 precursors into HEK-293 cells. 2 d after 
transfection, dual luciferase activity was measured. ***, P < 0.001 compared with cells transfected with con mimics. (N) HA-smad7–expressing vector that 
contains wild-type or mutant 3 UTR of the mouse smad7 gene was cotransfected with control vectors or vectors expressing miR-21 into HEK-293 cells. 
2 d after transfection, HA-smad7 levels were determined. Experiments in M and N were performed two to three times with similar results.
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Immunohistochemistry. Mouse lungs were inflated with 10% formalin 
solution and embedded in paraffin. 10-µm-thick sections were prepared,   
deparaffinized with xylene, and then rehydrated in water through graded 
ethanol. Antigen retrieval was performed in a pressure cooker in Tris-EDTA 
solution, pH 9.0, for 5 min. After incubation in TBST buffer for 10 min and 
3% H2O2 for 10 min, the sections were washed with TBST and blocked 
with avidin/biotin blocker and affinity-purified goat anti–mouse IgG (H+L). 
The sections were then incubated with mouse anti–-SMA (Sigma-Aldrich) 
overnight at 4°C, secondary antibody for 45 min, avidin-HRP for 45 min, 
and DAB chromagen, sequentially. Finally, the sections were counterstained 
with hematoxylin.
Collagen content determination. The right lungs from mice were collected 
and homogenized in 5 ml 0.5 M acetic acid in PBS containing 0.6% pepsin. The 
extracts were rotated at 4°C overnight and cleared by centrifugation at 13,200 
rpm for 15 min. Collagen content was measured using the Sircol Collagen Assay 
kit (Biocolor Ltd.) according to the manufacturer’s instructions. Collagen con-
tent is presented as g acid-soluble collagen/right lung.
Western blotting. Western blotting was performed as described previ-
ously (Liu et al., 2008). Mouse anti-Fn antibody, goat anti-Col1A1 anti-
bodies, rabbit anti-GAPDH antibodies, and rabbit anti-Spry1 antibodies 
were from Santa Cruz Biotechnology, Inc. Mouse anti–-SMA was from 
Sigma-Aldrich. Rabbit anti–p-Smad2, Smad-2, P-Erk, and Erk were from 
Cell Signaling Technology. Rabbit anti-Smad7 antibodies were from Thermo 
Fisher Scientific.
Luciferase  reporter  assay.  The  full-length  3  UTR  of  mouse  Smad7 
gene was amplified by PCR using mouse genomic DNA as a template. The 
primers were: sense 5-ACTAGTACCGTTCAAACTACTTGCTGCTA-
ACC-3 and antisense 5-AAGCTTTGCTAAATTTCCAATGAGAAT-
GCTTC-3. The PCR fragment was cloned downstream of the luciferase 
gene between the SpeI and HindIII sites in pMIR-Report (Applied Bio-
systems). To generate Smad7 3 UTR mutants containing mutations in the 
conserved miR-21 binding site, site-directed mutagenesis was performed 
using the wild-type 3 UTR as the template. In the 3 UTR mutant, the 
nucleotide sequence complementary to nt 2–5 of miR-21 was mutated to 
the same sequence as that in miR-21 (from AGCT to TCGA). 0.5 µg of 
the luciferase reporters containing the wild-type or mutant 3 UTR were 
cotransfected with control miRNA precursors or miR-21 precursors into 
HEK-293 cells. As an internal control, renilla luciferase reporters were also 
included. 2 d after transfection, the cells were collected and dual luciferase 
activities were measured according to the manufacturer’s instructions.
Masson’s trichrome assay. The assay was performed by the UAB Tissue 
Histology Core facility as described previously (Hecker et al., 2009).
H&E staining. The assay was performed by the UAB Tissue Histology 
Core facility as described previously (Hecker et al., 2009).
Statistical analysis. One-way ANOVA followed by the Holm-Sidak or 
Tukey-Kramer test was performed for multiple group comparisons. The 
Student’s t test was used for comparison between two groups. P < 0.05 was 
considered significant.
Online  supplemental  material.  Fig.  S1  shows  enhanced  expression 
of miR-21 in the lungs of mice with experimental lung fibrosis. Fig. S2 
shows that sequestering miR-21 attenuates experimental lung fibrosis in 
mice. Fig. S3 demonstrates that miR-21 is induced by TGF-1 and bFGF 
in human primary fibroblasts. Fig. S4 shows that miR-21 regulates Smad7 
and Spry1. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20100035/DC1.
G. Liu conceived of, designed, conducted, and supervised the experiments.  
A. Friggeri and Y. Yang contributed to mouse studies. J. Milosevic, Q. Ding,  
miRNA array. Total RNAs were isolated from mouse lungs harvested at   
d 0, 7, and 14 after bleomycin instillation (three mice per group) with the 
smiRNAeasy Mini kit (QIAGEN). The miRNA array was performed by 
Exiqon using miRCURY LNA microRNA Array (Exiqon). Array Express 
accession no. E-MEXP-2749.
Northern blotting. The assay was performed as described previously (Liu   
et al., 2009). In brief, total RNA (10 µg) was resolved on a 12% denatured 
polyacrylamide gel containing 8M urea. The RNA was then transferred to   
a Hybond nylon membrane (GE Life Sciences). After UV cross-linking, the 
membrane was incubated in prehybridization buffer (50% formamide [USB], 
0.5% SDS, 5xSSC [USB], 5×Denhardt’s solution [USB], and 20 µg/ml 
sheared, denatured, salmon sperm DNA [Invitrogen]) at 55°C for 30 min and 
then hybridized with specific [P32]-labeled human LNA miR-21 probes   
(Exiqon) at 55°C for 24 h. The membrane was washed for 10 min three times 
with buffer (0.5% SDS, 2xSSC) and exposed to film. After hybridization with 
miR-21 probes, the membrane was stripped and reblotted with specific [P32]-
labeled mouse U6 probes (Exiqon) as loading controls.
Real-time PCR. The assay was performed as described previously (Liu   
et al., 2009). Taqman probes for hsa-miR-21, hsa-miR-155, and mouse 
Sno135  were  purchased  from  Applied  Biosystems.  The  expression  of   
-SMA, fibronectin, Col1A1, Col1A2, and TGF-1 was determined using 
the SYBR Green Master Mix kit (Roche). GAPDH or HPRT was used as 
an internal control. The sequences of the primers: mouse HPRT: sense,   
5-GGGACATAAAAGTTATTGGTGGAGATG-3; antisense, 5-CAA-
CAACAAACTTGTCTGGAATTTCAA-3.  Human  fibronectin:  sense, 
5-GTGTTGGGAATGGTCGTGGGGAATG-3; antisense, 5-CCAAT-
GCCACGGCCATAGCAGTAGC-3. Mouse fibronectin: sense, 5-TCT-
GGGAAATGGAAAAGGGGAATGG-3; antisense, 5-CACTGAAGCA-
GGTTTCCTCGGTTGT-3. Human -SMA: sense, 5-CATCACCAA-
CTGGGACGACATGGAA-3;  antisense,  5-GCATAGCCCTCAT-
AGATGGGGACATTG-3. Mouse -SMA: sense, 5-GACGCTGAAG-
TATCCGATAGAACACG-3; antisense 5-CACCATCTCCAGAGTC-
CAGCACAAT-3. Mouse TGF-1: sense, 5-AGCGGACTACTATGC-
TAAAGAGGTCACCC-3; antisense, 5-CCAAGGTAACGCCAGGAA-
TTGTTGCTATA-3. Mouse Col1A1: sense, 5-GGAGGGCGAGTGCT-
GTGCTTT-3; antisense, 5-GGGACCAGGAGGACCAGGAAGT-3. 
Mouse Col1A2: sense, 5-TGGTCTTACTGGGAACTTTGCTGC-3; 
antisense,  5-ACCCTGTGGTCCAACGACTCCTCTC-3.  Mouse 
GAPDH: sense, 5-CGACTTCAACAGCAACTCCCACTCTTCC-3; 
antisense, 5-TGGGTGGTCCAGGGTTTCTTACTCCTT-3. Human 
GAPDH:  sense,  5-GCTGGCGCTGAGTACGTCGTGGAGT-3;  anti-
sense, 5-CACAGTCTTCTGGGTGGCAGTGATGG-3.
In situ hybridization (ISH). The assay was performed as described previ-
ously (Obernosterer et al., 2007). In brief, mice were sacrificed and the lungs 
inflated with intratracheal injection of 1 ml OCT (Thermo Fisher Scientific). 
The lungs were then embedded with OCT, and 10-µm-thick frozen sections 
prepared. The sections were dried at room temperature for 30 min, followed 
by fixation in 4% paraformaldehyde (Thermo Fisher Scientific) for 30 min. 
The sections were treated in acetylation solution for 10 min and then in PBS 
containing 10 µg/ml proteinase K (Sigma-Aldrich) for 5 min. Sections were 
then blocked with hybridization solution for 4 h at room temperature and in-
cubated with digoxigenin (Dig)-conjugated miR-21 probes (Exiqon) or Dig-
conjugated control probes with scrambled sequence (Exiqon) overnight. The 
sections were washed with 0.2× SSC followed by incubation with HRP-
conjugated anti-Dig antibody (Roche) overnight at 4°C. After washing three 
times with buffer B1, the sections were developed with NBT/BCIP (Roche) 
for 24 h, with light blue cytoplasmic staining being positive. To determine 
the colocalization of miR-21 and -SMA, FITC-conjugated miR-21 probes 
(Exiqon) in combination with Cy3-conjugated anti–-SMA antibody 
(Sigma-Aldrich) were used in the hybridization assays. The sections were ex-
amined by confocal microscopy. miR-21 was shown as green fluorescence 
and -SMA as red fluorescence.JEM VOL. 207, August 2, 2010  1597
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